CA2100777C - Pharmaceutical composition containing granisetron and dexamethasone - Google Patents

Pharmaceutical composition containing granisetron and dexamethasone Download PDF

Info

Publication number
CA2100777C
CA2100777C CA002100777A CA2100777A CA2100777C CA 2100777 C CA2100777 C CA 2100777C CA 002100777 A CA002100777 A CA 002100777A CA 2100777 A CA2100777 A CA 2100777A CA 2100777 C CA2100777 C CA 2100777C
Authority
CA
Canada
Prior art keywords
granisetron
dexamethasone
vomiting
nausea
cytotoxic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002100777A
Other languages
French (fr)
Other versions
CA2100777A1 (en
Inventor
Gareth John Sanger
Christopher Stuart Dott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2100777A1 publication Critical patent/CA2100777A1/en
Application granted granted Critical
Publication of CA2100777C publication Critical patent/CA2100777C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical product comprising granisetron and dexamethasone as a combined preparation far simultaneous, sepa-rate or sequential use in the treatment and/or prevention of nausea and vomiting.

Description

WO 92/12716 ~ ~ ~,~ ~f ~~ ,,~ r~ PCT/GB92/00091 Pharmaceutical composition containing granisetron and dexamethasone This invention relates to the use of a compound having 5-HT3 receptor antagonist activity and dexamethasone in the treatment of emesis, and to pharmaceutical compositions containing the two compounds.
EP-A-200449 tBeecham Group p.l.c.), Example 6 discloses granisetron, and its use as an anti-emetic, especially 1o useful in treating cytotoxic agent-induced nausea and vomiting. All references herein to granisetron include pharmaceutically acceptable salts, such as the hydrochloride, and solvates, such as hydrates.
i5 The anti-emetic properties of granisetron are potentially enhanced by administering the compound in conjunction with systemic corticosteraids, such as dexamethasone.
Dexamethasone is a systemic anti-inflammatory corticosteroid, which is known to have anti-emetic 20 properties and to be useful in the treatment of emesis resulting from chemotherapy, especially cancer chemotherapy involving the use of, for example, cisplatin.
Accordingly, the present invention provides a pharmaceutical 25 product comprising granisetron and dexamethasone as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of nausea and vomiting.
3o The present invention also provides a method of treatment and/or prophylaxis of nausea and vomiting, which comprises administering to a human or animal subject, granisetron and dexamethasone or a pharmaceutically acceptable salt or ester thereof.
The invention further provides the use of granisetron for the manufacture of a medicament for administration in WO 92/12716 ~~/~~~ PCT/GB92/00091 - ,-.~_ conjunction with dexame'thasone or a pharmaceutically acceptable salt or ester thereof, for the treatment and/or prevention of nausea and vomiting.
Co-administration of granisetron with dexamethasone is particularly useful for the treatment and/or prevention of nausea and vomiting associated with chemotherapy using cytotoxic drugs, especially cancer chemotheraphy involving the use of, for example, platinum complexes such as cisplatin or carboplatin, or cylcophosphamide or doxorubicin. Such co-administration may also reduce delayed or prolonged nausea and vomiting associated with this type of chemotherapy. Particular note should also be made of the use in the treatment of nausea and vomiting associated with other cytotoxic agents, such as that associated with radiation treatment.
Granisetron and dexamethasone or a pharmaceutically acceptable salt or ester thereof, may be administered as a 2o single pharmaceutical composition comprising effective amounts of the two active ingredients. Alternatively the two active ingredients may be co-administered in the form of two separate pharmaceutical compositions for simultaneous or sequential use.
Suitable pharmaceutically acceptable salts of granisetron for use according to the invention include acid addition salts formed with organic or inorganic acids for example, hydrochlorides, hydrobromides, sulphates, phosphates, 3o citrates, fumarates and maleates. The solvates may, for example, be hydrates. A preferred form of granisetron for -use according to the invention is the hydrochloride.
Dexamethasone may be administered according to the invention as dexamethasone alcohol or in the form of a pharmaceutically acceptable salt or ester. Suitable salts and esters include the acetate, isonicotinoate, WO 92/12716 ~ ~~ ( '~ PCT/GB92/00091 phenylpropionate, pivalate, t-butyl acetate, trioxaundecanoate, disodium metasulphobenzoate and disodium phosphate.
A proposed dosage of granisetron for use according to the invention for administration to man (of approximately 70kg body weight), is 0.05 to 25mg., more preferably 0.05 to 20mg, and most preferably 0.1 to lOmg per unit dose, expressed as the weight of free base. A preferred dose of dexamethasone for use according to the invention is in the range of 0.5 to 20mg per dosage unit, expressed as the weight of the alcohol.
The unit doses may be administered, for example, 1 to 4 times per day. The exact dose will depend on the route of administration and the condition being treated, and it will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient as well as the severity of the condition to be treated.
When the two active ingredients are administered as separate preparations, they are preferably given enterally, such as orally or parenterally (e. g. intramuscularly or, more particularly, intravenously).
According to a further aspect the invention provides a pharmaceutical composition, for use in human or veterinary medicine, comprising the granisetron, and dexamethasone or a 3o pharmaceutically acceptable salt or ester thereof.
Compositions according to the invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus the compositions may, for example, be formulated for oral, buccal, parenteral ;~
2~.~fl'~7'~
or rectal administration. Compositions for administration by the oral route, in the form of for example tablets or capsules, are preferred.
Compositions for oral use such as tablets and capsules may be prepared by conventional means. with pharmaceutically acceptable excipients such as binding agents (e. g.
pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose): fillers (e. g. lactose, to microcrystalline cellulose or calcium hydrogen phosphate) lubricant (e. g. magnesium stearate, talc or silica);
disintegrants (e. g. potato starch or sodium starch glycollate); or wetting agent (e. g. sodium lauryl sulphate).
Tablets may be coated by methods well known in the art.
Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with 2o pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats): emulsifying agents (e. g. lecithin or acacia); non-aqueous vehzcles (e. g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils) and preservatives (e.g. methyl or propyl-~-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
Preparations for oral administration may be suitably formulated to give controlled release of one or both active ingredients.
For parenteral administration the compositions may be.
presented in a form suitable for bolus injection or continuous infusion. Formulations for injection may be WO 92/12716 ~ ~ ~ ~ ~ ~ ~ PCf/GB92/00091 presented in unit dosage form e.g. in syringes, ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredients may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free Water, before use.
E'or rectal administration the compositions may be formulated as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The pharmaceutical compositions of the invention may be prepared according to conventional techniques well known in the pharmaceutical industry. Thus, for example, the granisetron and the dexamethasone or dexamethasone salt or ester may be admixed together, if desired, with suitable excipients. Tablets may be prepared, for example, by direct compression of such a mixture. Capsules may be prepared by filling the blend along with suitable excipients into gelatin capsules, using a suitable filling machine.
Controlled release forms for oral or rectal administration may be formulated in a conventional manner associated with controlled release forms.
The compositions for use according to the invention may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Where the granisetron and the dexamethasone are intended fox administration as two separate compositions these may be presented in the form of, for example, a twin pack.

- 6- ,, .
2~.0~"~7'~ ._ , Clinical Studies FIRST STUDY
A randomised, double blind, parallel group study comparing the use of granisetron and/or dexamethasone for prophylactic control of cisplatin (>_ 50 mglm2) induced nausea and vomiting is carried out for a period of seven days.
Randomisation is stratified by cisplatin dose (50-79 mg/m2 and >_ 75 mg/m2). Patients receive either granisetron for seven days, granisetron and dexamethasone for seven days, or granisetron and dexamethasone for one day followed by dexamethasone for six days.
The following are evaluated:
o The improvement by dexamethasone of the efficacy of granisetron when both medications are given over a period of 24 hours and seven days.
o The efficacy improvement of dexamethasone in preventing delayed onset nausea and/or vomiting when granisetron is administered from day 2-7.
Patients receiving cisplatin (>_50 mg/m2) therapy for malignant disease are randomised in a double blind fashion, stratified according to cisplatin dosage, to receive the study medication.
The study design consists of 3 treatment arms:
1. Placebo (saline) 15 minutes infusion to be completed 20 minutes prior to cisplatin infusion (TIME 0) and granisetron 3 mg I.V. 15 minute infusion to be completed 5 min prior to TIME 0 followed by granisetron 1 mg p.o. at 6 and 12h. Granisetron 1 mg p.o. B.I.D. begins at 24h for 6 consecutive days.

2. Dexamethasone 10 mg I.V. 15 minute infusion to be completed 20 munutes prior to cisplatin infusion (TIME
0) and granisetron 3 mg I.V. 15 minute infusion to be completed 5 min prior to TIME ) followed by granisetron 1 mg p.o. at 6 and 12h.
Granisetron 1 mg p.o. B.I.D. and dexamethasone 8 mg p.o. B.I.D. begins at 24h for 6 consecutive days.
io 3. Dexamethasone lOmg I.V. 15 minute infusion to be completed 20 minutes prior to cisplatin infusion (TIME
0) and granisetron 3 mg I.V. 15 minute infusion to be completed 5 min prior to TIME 0 followed by granisetron 1 mg p.o. at 6 and 12. Dexamethasone 8 mg p.o. B.I.D. begins at 24h for 6 consecutive days.
Patients disease state is assessed using the WHO
classification and they must have a score of 2 or less. All 2o patients are naive to cytotoxic therapy to avoid anticipatory emesis.
Patients who develop nausea and vomiting after their cisplatin therapy may be given up to four doses of prochlorperazine (10 mg suppositories) per day. If nausea and vomiting continue after this such that other anti-emetics have to be given, the physician decides whether or not to stop the study medication and/or treat with standard anti-emetics. As far as is medically safe, 3o patients remain on the study medication for as much of the 7 day treatment period as possible.
The primary efficacy assessments in the study are the percentage of Complete Responders, the time to first vomiting, and the use of other anti-emetics over the seven day period.
Secondary efficacy assessments of nausea and vomiting during s the first 24 hours determine the increase in efficacy of granisetron by dexamethasone. As well, nausea and vomiting assessments after the first 29 hours determine the increase in efficacy of dexamethasone by granisetron in the maintenance phase of treatment.
SECOND STUDY
A randomised, double blind, parallel group study is carried out, comparing oral granisetron (1.0 mg bd) with oral granisetron in combination with dexamethasone (12 mg iv) on the first day only and a conventional anti-emetic therapy, (metoclopramide 7mg/kg iv plus dexamethasone 12 mg iv on the first day, followed by metoclopramide 10 mg tds po) over a 7 day period in controlling cisplatin induced nausea and 2o vomiting.
The following are primary efficacy assessments:
o The percentage of complete responders over the seven 2s day period.
o The time to less than complete response and use of other antiemetics using survival methods over the seven day period.
The following are secondary efficacy assessments:
o The percentage of complete responders over the crtical 24 hour period.
o Subjective symptom scoring for nausea and vomiting.

Claims (16)

CLAIMS:
1. A pharmaceutical product comprising granisetron and dexamethasone for simultaneous, separate or sequential use in the treatment and/or prevention of nausea and vomiting.
2. Use of granisetron and dexamethasone or a pharmaceutically acceptable salt or ester thereof for treatment and/or prophylaxis of nausea and vomiting in a human or animal subject.
3. The use of granisetron for the manufacture of a medicament for administration in conjunction with dexamethasone or a pharmaceutically acceptable salt or ester thereof, for the treatment and/or prevention of nausea and vomiting.
4. A pharmaceutical composition, for use in human or veterinary medicine, comprising granisetron, and dexamethasone or a pharmaceutically acceptable salt or ester thereof.
5. A product according to claim 1, wherein the nausea and vomiting is cytotoxic agent-induced.
6. A product according to claim 5, wherein the cytotoxic agent is cisplatin.
7. A product according to any one of claims 1, 5-6, wherein the granisetron is in the form of the hydrochloride salt.
8. The use according to claim 2, wherein the nausea and vomiting is cytotoxic agent-induced.
9. The use according to claim 8, wherein the cytotoxic agent is cisplatin.
10. The use according to any one of claims 2 and 8-9, wherein the granisetron is in the form of the hydrochloride salt.
11. The use according to claim 3, wherein the nausea and vomiting is cytotoxic agent-induced.
12. The use according to claim 11, wherein the cytotoxic agent is cisplatin.
13 The use according to any one of claims 3 and 11-12, wherein the granisetron is in the form of the hydrochloride salt.
14. The composition according to claim 4 for use in the treatment and/or prevention of nausea and vomiting, wherein the nausea and vomiting is cytotoxic agent-induced.
15. The composition according to claim 14, wherein the cytotoxic agent is cisplatin.
16. The composition according to any one of claims 4 and 14-15, wherein the granisetron is in the form of the hydrochloride salt.
CA002100777A 1991-01-19 1992-01-16 Pharmaceutical composition containing granisetron and dexamethasone Expired - Lifetime CA2100777C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919101221A GB9101221D0 (en) 1991-01-19 1991-01-19 Pharmaceuticals
GB9101221.1 1991-01-19
PCT/GB1992/000091 WO1992012716A1 (en) 1991-01-19 1992-01-16 Pharmaceutical composition containing granisetron and dexamethasone

Publications (2)

Publication Number Publication Date
CA2100777A1 CA2100777A1 (en) 1992-07-20
CA2100777C true CA2100777C (en) 2003-08-19

Family

ID=10688722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002100777A Expired - Lifetime CA2100777C (en) 1991-01-19 1992-01-16 Pharmaceutical composition containing granisetron and dexamethasone

Country Status (12)

Country Link
EP (1) EP0567498A1 (en)
JP (1) JP3521143B2 (en)
KR (1) KR930702991A (en)
AU (1) AU658169B2 (en)
CA (1) CA2100777C (en)
GB (1) GB9101221D0 (en)
IE (1) IE920148A1 (en)
MX (1) MX9200214A (en)
NZ (1) NZ241337A (en)
PT (1) PT100033B (en)
WO (1) WO1992012716A1 (en)
ZA (1) ZA92343B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US20060263421A1 (en) * 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
US20080241231A1 (en) * 2007-02-21 2008-10-02 Victory Pharma, Incorporated Transdermal delivery of dexamethasone and promethazine
JP5537104B2 (en) * 2009-09-16 2014-07-02 テルモ株式会社 Antiemetic
KR101368587B1 (en) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 Composition for prevention of nausea or vomiting
CN103222977A (en) * 2013-05-22 2013-07-31 南京工业大学 Granisetron and dexamethasone compound transdermal controlled-release patch and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
JPH06507152A (en) 1994-08-11
WO1992012716A1 (en) 1992-08-06
IE920148A1 (en) 1992-07-29
JP3521143B2 (en) 2004-04-19
MX9200214A (en) 1992-08-01
NZ241337A (en) 1994-07-26
AU1164192A (en) 1992-08-27
AU658169B2 (en) 1995-04-06
PT100033B (en) 1999-09-30
EP0567498A1 (en) 1993-11-03
PT100033A (en) 1993-02-26
GB9101221D0 (en) 1991-02-27
KR930702991A (en) 1993-11-29
CA2100777A1 (en) 1992-07-20
ZA92343B (en) 1992-12-30

Similar Documents

Publication Publication Date Title
EP0533280B2 (en) Novel medical use for tachykinin antagonists
EP0226266B1 (en) Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments
JP4925074B2 (en) A pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
AU765749B2 (en) Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
EP0230370A2 (en) Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
JP2004508311A (en) Pharmaceutical compositions for headache, migraine, nausea and vomiting
US4804669A (en) Treatment of pain with a piperidine
US5929059A (en) Pharmaceutical compositions containing granisetron and dexamethasone
US5578632A (en) Medicaments for the treatment of gastrointestinal dysfunction
KR20010015918A (en) Fluoxetine Hydrochloride for Decreasing Hot Flashes
JPH0157093B2 (en)
CA2100777C (en) Pharmaceutical composition containing granisetron and dexamethasone
JP2000513331A (en) Paroxetine in the treatment of depression
EP0190851B1 (en) Improved antiinflammatory composition
IE913580A1 (en) Medicaments
AU626010B2 (en) Medicaments
US5240954A (en) Medicaments
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
EP0059031B1 (en) Analgesic and anti-inflammatory composition
CA1172566A (en) Method for producing pharmaceutical preparation
IE43955B1 (en) Pharmaceutical composition and dosage units thereof
US5153216A (en) Method for treating chest pain
US3773937A (en) Method of treatment
MXPA00000522A (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry